ANRS HC 22, PEGLIST-C, Multicenter, Randomized Controlled Trial of Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C, Non 2 or 3 Genotypes and Insulin Resistance.

Trial Profile

ANRS HC 22, PEGLIST-C, Multicenter, Randomized Controlled Trial of Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C, Non 2 or 3 Genotypes and Insulin Resistance.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Pioglitazone (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C; Insulin resistance
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PEGLIST-C
  • Most Recent Events

    • 23 Jan 2017 Status changed from active, no longer recruiting to discontinued.
    • 11 Jul 2012 Last checked against European Clinical Trials Database record.
    • 21 Feb 2012 Actual patient number (40) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top